News Breaks |
|
|
| February 10, 2013 |
| 18:55 EDT |  | NVO, SNY, LLY | Novo Nordisk receives FDA 'Complete Response Letter" for Tresiba and Ryzodeg
Novo Nordisk announced that on 8 February it received a Complete Response Letter from the US Food and Drug Administration, FDA, regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart). A complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form. Reference Link |
|
|
News For NVO;SNY;LLY From The Last 14 Days Check below for free stories on NVO;SNY;LLY the last two weeks. |
|
|
| May 23, 2013 |
| 11:54 EDT | | NVO | Novo Nordisk reports 8% weight loss in phase 3a trial with liraglutide
 Subscribe for More Information |
|
| 08:18 EDT | | SNY | Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi
Subscribe for More Information |
|
| May 21, 2013 |
| 07:44 EDT |  | SNY | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:24 EDT | | LLY | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 17:26 EDT | | SNY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 11:27 EDT | | SNY | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 08:03 EDT | | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
Subscribe for More Information |
|
| 05:18 EDT | | SNY | Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information |
|
| May 16, 2013 |
| 08:55 EDT | | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 15:16 EDT | | SNY | Sanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information |
| |
| 05:39 EDT | | SNY | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 09:44 EDT |  | SNY | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:30 EDT | | SNY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
|
|
|
|
